US EditionPublished • loading... • Updated
Eli Lilly Becomes First Trillion-Dollar Health Company
- On Nov. 21, Eli Lilly reached a $1 trillion market valuation in trading Friday, briefly crossing the threshold before its stock pulled back in U.S. stock markets.
- Lilly's surge follows sales of Mounjaro and Zepbound, which generated $11.54 billion and $4.93 billion by 2024, while shares rose more than 36% this year.
- After winning approvals, Lilly now faces intensified competition as Pfizer paid $10 billion for Metsera earlier this month and two new injectable obesity drugs enter trials.
- Some analysts predict the market could exceed $150 billion by the early 2030s, and Eli Lilly expects continued growth as insurance and approvals expand access with an oral version next year.
- As a rare non-tech trillion-dollar firm, Eli Lilly is the first healthcare company to reach $1 trillion and only the second after Warren Buffett's Berkshire Hathaway, founded in 1876 with milestones like 1923's insulin and Prozac.
Insights by Ground AI
Podcasts & Opinions
34 Articles
34 Articles
Coverage Details
Total News Sources34
Leaning Left7Leaning Right3Center8Last UpdatedBias Distribution44% Center
Bias Distribution
- 44% of the sources are Center
44% Center
L 39%
C 44%
R 17%
Factuality
To view factuality data please Upgrade to Premium
